filmov
tv
Bristol Myers Squibb plans $2 billion in cost cuts by 2027
Показать описание
Bristol Myers Squibb plans to cut $2 billion in costs by 2027 to support growth and drug development, addressing revenue loss from key drugs losing exclusivity. Despite strong fourth-quarter earnings, its 2025 guidance is below expectations.
Key Points:
- $2 billion cost cuts by 2027; $1.5 billion by 2025 for drug development.
- Preparing for revenue loss from Eliquis and Opdivo losing exclusivity.
- Strong Q4 earnings, but 2025 guidance below expectations.
---------------------------------------------------------------
Follow Us:
Key Points:
- $2 billion cost cuts by 2027; $1.5 billion by 2025 for drug development.
- Preparing for revenue loss from Eliquis and Opdivo losing exclusivity.
- Strong Q4 earnings, but 2025 guidance below expectations.
---------------------------------------------------------------
Follow Us:
0:03:18
0:02:40
0:02:46
0:02:08
0:02:50
0:04:38
0:07:26
0:12:34
0:01:05
0:00:57
0:31:25
0:07:54
0:06:14
0:12:27
0:12:40
0:05:39
0:02:48
0:03:27
0:07:52
0:04:48
0:01:40
0:04:21
0:08:15
0:00:36